VikkiAnnCanfieldMD

Oncology • Oklahoma City, OK

Breast Cancer, Head & Neck Cancer, Hematologic Oncology

Dr. Vikki A Canfield is retired

Join to view full profile

Dr. Canfield is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Canfield's full profile

Already have an account?

Office
11800 Quail Creek Road
Oklahoma City, OK 73120
Is this information wrong?

Summary

Dr. Vikki Canfield is an oncologist in Oklahoma City, OK and is affiliated with multiple hospitals in the area, including Mercy Hospital Oklahoma City, Mercy Hospital Ardmore, AllianceHealth Clinton, and St Edward Mercy Medical Center. She received her medical degree from University of Washington School of Medicine and has been in practice 37 years. She specializes in head & neck cancer and hematologic oncology and is experienced in hematologic oncology, head and neck cancer, and breast oncology.

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1986 - 1988
University of WashingtonFellowship, Hematology and Medical Oncology, 1983 - 1986
Providence Health & ServicesResidency, Internal Medicine, 1980 - 1983
University of Washington School of MedicineClass of 1980

Certifications & Licensure

OK State Medical License 1992 - 2023
OR State Medical License 1981 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer Start of enrollment: 2010 Jan 18
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
Terminated
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

11 citations
Treatment of Base of Tongue Cancer With Paclitaxel, Ifosfamide, and Cisplatinum Induction Chemotherapy Followed by Chemoradiotherapy†
Samuel Brandon Hancock, Greg A. Krempl, Vikki A. Canfield, Carl Bogardus, Kiarash Kojouri, S K. Kaneaster, Jesus E. Medina> ;The Laryngoscope. 2008 Aug 1
15 citations
Sinonasal neuroendocrine carcinoma in association with SIADH
Nilesh R. Vasan, Jesus E. Medina, Vikki A. Canfield, Elizabeth M. Gillies> ;Head & Neck. 2004 Jan 1
1 citations
A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.
David M. Loesch, Lina Asmar, Vikki A. Canfield, Gregory A. Parker, Harry E. Hynes, Peter G. Ellis, William A. Ferri, Nicholas J. Robert> ;Breast Cancer Research and Treatment. 2003 Jan 1
9 citations
Results of phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and...
Avi Khafif, Vikki A. Canfield, Elizabeth Syzek, Jesus E. Medina> ;American Journal of Otolaryngology. 2003 Jan 1
10 citations
Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.
Charles E. Geyer, Stephanie Green, Carol M. Moinpour, Janet O'Sullivan, Donna K. Goodwin, Vikki A. Canfield, Frederick J. Meyers, C. Kent Osborne, Silvana Martino> ;Breast Cancer Research and Treatment. 1998 Sep 1
14 citations
A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Scott Saxman, Beth Mann, Vikki A. Canfield, Patrick J. Loehrer, Everett E. Vokes> ;American Journal of Clinical Oncology. 1998 Aug 1
8 citations
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group.
P. N. Grozea, John Crowley, Vikki A. Canfield, Laura Kingsbury, S. William Ross, German Beltran, Leslie R. Laufman, Geoffrey R. Weiss, Robert B. Livingston> ;Cancer. 1997 Sep 15
11 citations
2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas.
Vikki A. Canfield, Julie M. Vose, Patricia Guiney, Bronwyn Bennett, Craig R. Nichols> ;Leukemia & Lymphoma. 1997 Jan 1
2 citations
A phase II trial of gallium nitrate in advanced previously untreated colorectal cancer.
Vikki A. Canfield, Alan P. Lyss> ;Investigational New Drugs. 1993 Jan 21
6 citations
An unusual mediastinal tumor in a patient with AIDS.
Valerie C. Rohlman, Vikki A. Canfield, Ronald A. Greenfield> ;The American Journal of Medicine. 1993 Feb 1
ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial.
Schulz, J., Keller, A., Canfield, V., Parker, G., Douglass, E.> ;Am J Clin Oncol. 2004 Aug
Join now to see all

Hospital Affiliations

Mercy Hospital Oklahoma CityOklahoma City, Oklahoma
Mercy Hospital ArdmoreArdmore, Oklahoma
AllianceHealth ClintonClinton, Oklahoma
Mercy Hospital Fort SmithFort Smith, Arkansas